What s New in Eosinophilic GI Disorders & Celiac Disease. John Garber, MD Gastrointestinal Unit Massachusetts General Hospital Harvard Medical School

Transcription

1 What s New in Eosinophilic GI Disorders & Celiac Disease John Garber, MD Gastrointestinal Unit Massachusetts General Hospital Harvard Medical School

2 Advisor to NIMA labs Disclosures

3 Learning Objectives for Eosinophilic Esophagitis 1. Understand the clinical features of presentation of this emerging allergic disorder 2. Identify populations with increased prevalence requiring heightened index of suspicion 3. Understand the current rational for and approaches to treatment

4 Case: chronic dysphagia in a 32 year-old man CC: 32 year-old man with difficulty swallowing HPI: Since college, dysphagia is present 3-4 times/week, usually when eating out at a restaurant. Episodes of food sticking will typically last for 15 minutes to an hour, and generally resolve with drinking water. He admits to being a lifelong slow eater and always has water with meals. About 3 months ago, started on omeprazole 40 mg/day and has been taking this since. Symptoms have partially improved with PPI. PMH: seasonal allergies, asthma as a child Medications: omeprazole 40 mg once a day, occasional albuterol

5 Case: chronic dysphagia in a 32 year-old man Endoscopy: Pathology: FINAL PATHOLOGIC DIAGNOSIS: A. ESOPHAGUS BIOPSY, DISTAL: Active esophagitis with peak intraepithelial eosinophil count exceeding 40 per HPF. Basal cell hyperplasia. Superficial layering of eosinophils is present. Lamina propria fibrosis. B. ESOPHAGUS BIOPSY, MID: Active esophagitis with peak intraepithelial eosinophil count exceeding 40 per HPF. Basal cell hyperplasia. Superficial layering of eosinophils is present. Lamina propria fibrosis.

6 Definition and Differential Diagnosis Eosinophilic esophagitis: a chronic, immune-mediated or antigen-mediated esophageal disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. Symptoms include feeding problems, vomiting, and abdominal pain in children, and dysphagia and food impaction in adolescents and adults. Esophageal mucosal eosinophilia of at least 15 eosinophils per high-power field. Other causes, particularly GERD, must be ruled out. Other causes of esophageal eosinophilia (parasitic infection, allergic vasculitis, esophageal leiomyomatosis, and Crohn s disease of the esophagus) are rare. Furuta and Katzka NEJM 2015

7 EoE is a Th2-predominant disease induced primarily by food antigens Amino-acid based elemental diet leads to disease remission; reintroduction of food leads to relapse IL-13 is significantly increased in esophageal tissues in active EoE About 20% of the EoE transcriptome is IL-13-driven Th2 cytokines and TSLP direct recruitment of eosinophils, IgE+ mast cells, Th2 lymphocytes, basophils and NK cells

8 Evidence that EoE is not primarily an IgEmediated food allergy Omalizumab (anti-ige) has not been effective EoE-like disease can be induced in IgE- and B cell-ko mice IgE based blood and skin testing does not reliably identify food antigen triggers in EoE

9 Pathogenesis

10 Epidemiology of EoE ICD-9 code established in 2008 Estimated prevalence of per 100,000 in the U.S. Higher in certain subpopulation: 6% of patients undergoing upper endoscopy for any reason; 15% of patients undergoing EGD for dysphagia, 50% of patients who present with a food impaction Described in all age groups, but predominantly affects white men, with onset from school age to midlife The prevalence is highest among men years old, with a rate of 114.6/100,000 persons. Noel NEJM 2004 Prasad CGH 2009 Dellon CGH 2014

11 Clinical presentation of EoE varies by age <5 years of age Failure to thrive Feeding difficulties Gagging on solid foods 6-14 years of age Vomiting Abdominal pain Dysphagia >15 years Dysphagia Food impaction Strictures

12 Mucosal changes in active EoE normal EoE variations Dellon CGH 2013

13 Histology of EoE Eosinophils Microabscess Basal-zone hyperplasia

14 EoE leads to progressive strictures and esophageal fibrosis EoE Normal GERD EoE Lucendo et al J Allergy Clin Immunol. 2011

15 Age at diagnosis, duration of EoE symptoms and risk of stricture

16 Age at diagnosis, duration of EoE symptoms and risk of stricture at MGH

17 Contrast radiography often reveals strictures and narrowing not apparent on endoscopy Lee at al CHG 2012

18 Measurement of esophageal distensibility with Functional Lumen Imaging Probe (EndoFLIP)

19 Measurement of esophageal distensibility with Functional Lumen Imaging Probe (EndoFLIP)

20 Measurement of esophageal distensibility with Functional Lumen Imaging Probe (EndoFLIP) Therap Adv Gastroenterol Mar;6(2):97-107

21 Treatment of EoE The goals of treatment are to reduce dysphagia symptoms, prevent food impactions and risk of perforation, and prevent progressive esophageal fibrosis and strictures. There are currently no FDA-approved treatments for EoE Currently, the main approaches to treatment are immune suppression or dietary modification. Endoscopic dilation remains an important aspect of therapy.

22 Corticosteroids in the treatment of EoE Fluticasone: Children: 50% complete response, 95% partial response (symptoms and histology) Adults: 62% histologic response, but no significant improvement in symptoms Budesonide: Adults: 72% remission (<5 eos/hpf), ~75% symptom improvement after 15 days. Typical initial duration of 8 weeks Dellon et al. AJG 2013

23 Corticosteroids in the treatment of EoE EoE will recur in the majority of patients after stopping steroid therapy. 91% of patients had recurrent symptoms at a mean of 8.8 months after treatment was completed; 69% repeated steroid treatment at least once. Helou et al (2008) Dellon et al. AJG 2013

24 Elimination diets in adults with EoE Components of a 6-food elimination diet: * Wheat * Dairy * Eggs * Soy * Peanut and tree nuts * Fish and shellfish

25 Elimination diets in adults with EoE Eosinophil counts Symptom scores Eosinophil counts with reintroduction Gonsalves et al. reported 50 adult subjects with EoE treated with 6 food elimination diet (milk, soy, egg, wheat, peanuts/tree nuts, and shellfish/fish) for 6 weeks. Mean peak eosinophil count 34 8/HPF (proximal) Mean peak eosinophil count 44 13/HPF (distal) 70% had peak counts of <10 eos/hpf after SFED Symptom scores decreased in 94% Gonsalves et al Gastro 2012

26 Elimination diets in adults with EoE Eosinophil counts Symptom scores Eosinophil counts with reintroduction Skin prick testing (SPT) accurately predicted only 13% of causal agents, and 67% of patients who had a food trigger identified by the reintroduction process had a negative SPT to all foods. The most common food triggers were wheat (60%) and milk (50%), followed by soy (10%), nuts (10%), and egg (5%). Gonsalves et al Gastro 2012

27 Elimination diets in adults with EoE Components of a 6-food elimination diet: * Wheat * Dairy * Eggs * Soy * Peanut and tree nuts * Fish and shellfish Implicated in 50-60% of all cases

28 General approach to EoE diagnosis and treatment

29 Takeaway points in EoE Consider EoE in any patient with chronic dysphagia or history of food impaction Can present at any age 0-99 Have a high suspicion in men in their 3 rd and 4 th decades of life, especially if other atopic history (asthma, eczema, food allergies) EGD or barium esophagram are reasonable first steps Diagnosis and treatment are critical to reduce the risk of progressive fibrosis and esophageal stricture.

30 Celiac Disease

31 Learning Objectives for Celiac Disease 1. Understand the definitions of gluten, celiac disease and nonceliac gluten-sensitivity 2. Review the typical and atypical presentations of celiac disease involving both intestinal and extra-intestinal sites 3. Review the requirements and pitfall in the serologic and histologic diagnosis of celiac disease 4. Understand the current approach to therapy and preview promising non-dietary therapies currently in development

32 History Aretaeus of Cappadocia (c. 100 A.D.) If the stomach be irretentive of the food and if it pass through undigested and crude, and nothing ascends into the body, we call such persons coeliacs.

33 History Dr. Mathew Baillie (1800s) Some patients have appeared to derive considerable advantage from living almost entirely upon rice. Samuel Gee (1888): On the Coeliac Affection : if the patient can be cured at all, it must be by means of diet.

34 History Willem-Karel Dicke (1944) In recent literature it is stated that the diet of Haas and Fanconi gives the best results in the treatment of patients suffering from coeliac disease. At present these items are not available. Therefore, I give a simple diet, which is helping these children at this time of rationing. The diet should not contain any bread or rusks. A hot meal twice a day is also well tolerated. The third meal can be sweet or sour porridge (without any wheat flour).

35 The Modern Definition of Celiac Disease Celiac disease is a chronic, small intestinal, immune-mediated enteropathy that is precipitated by dietary gluten in genetically predisposed individuals. Ludvigsson et al: The Oslo definitions for coeliac disease and related terms. Gut 2013

36 What is gluten?

37 What is gluten?

38 Green and Cellier NEJM 2007 Pathophysiology

39 Discovery of tissue transglutaminase (TTG) Anti-gliadin antibodies first characterized in 1980s EMA assay 1985 unknown antigen in the endomysium surrounding smooth muscle TTG identified as the autoantigen in the EMA assay (1997) The function of TTG in deamidating gluten peptides described enhanced presentation by HLA-DQ2 (1998)

40 Deamidation enhances presentation on HLA-DQ2- encoded MHC; transamidation generates neoepitopes and anti-ttg autoantibodies Di Sabatino et al. Autoimmunity Rev 2012

41 Endoscopic Appearance Normal healthy duodenum Active celiac

42 Histopathology Celiac duodenum Normal duodenum Marsh Classification Sleisenger and Fordtran 2006

43 The family of human transglutaminases Class Synonym Tissue Clinical association TG1 Keratinocyte transglutaminase skin ichthyosis TG2 Tissue transglutaminase gut, kidney, lung, hematopoietic, smooth muscle, endothelium Celiac, nephropathy, cirrhosis TG3 Epidermal transglutaminase skin Dermatitis herpetiformis TG4 Prostatic secretory transglutaminase prostate Prostate cancer TG5 Transglutaminase X skin Dermatitis herpetiformis TG6 Neuronal transglutaminase CNS Gluten ataxia Blood coagulation Factor XIIIa Transglutaminase Factor XIIIa plasma coagulopathy

44 Dermatitis herpetiformis: a model for extraintestinal manifestations of celiac disease Gluten is the dietary trigger of DH Urticarial, vesicular, or bullous lesions, usually localized to the scalp, shoulders, elbows, knees, buttocks IgA deposits in the upper dermis Responds gradually to gluten free diet

45 Dermatitis herpetiformis: a model for extraintestinal manifestations of celiac disease intestine Dermal-epidermal junction Anti-TG2 IgA Anti-TG3/TG5 IgA INF-γ, TNF-α, IL-2, IL-6, TGF-β Complement activation Inflammatory infiltrate

46 Gluten ataxia intestine Anti-TG2 IgA Anti-TG6 IgA Cerebellum vasculature INF-γ, TNF-α, IL-2, IL-6, TGF-β Complement activation Inflammatory infiltrate

47 Celiac prevalence approaches 1% and appears to be increasing Current estimate 1 in 133 of average healthy U.S. 1 in 56 with related symptoms 1 in 22 in those with a first degree relative 1 in 236 African, Hispanic, Asian Projected number of celiac in US: million Actual number diagnosed ~50,000 For each case of CD, ~ 50 undiagnosed Population prevalence of celiac disease appears to be increasing (+TTG 0.2% in 1950 vs. 0.9% in 2000s) Fasano Arch Internal Med 2003 Abadie Ann Rev Immunol 2009 Rubio-Tapia A Gastro 2009

48 Prompt diagnosis is the exception On average patients have symptoms for a 4-10 years before diagnosis The majority of new diagnoses now present with non-classic symptoms to diverse medical specialties Ecchymosis Edema Dermatitis Amenorrhea, infertility Secondary hyperparathyroidism Obesity Constipation Anemia Bleeding disorders Abnormal LFTs Musculoskeletal abnormalities Neuropathy Ataxia Osteopenia Pathologic fractures Green et al AJG 2001, 2006

49 The Diagnosis of Celiac Disease Required: 1. Distal duodenal biopsy specimens demonstrating characteristic histologic changes 2. Positive CD-specific serologies (anti-ttg IgA or EMA) Supportive: 1. Genetic testing (HLADQ2/8 necessary but not sufficient) 2. Stool testing for steatorrhea 3. Radiology/barium studies (rarely) 4. Response to GFD or gluten challenge

50 Diagnosis Still Requires Small Intestine Biopsy Leffler and Schuppan AJG 2010

51 5 mini-cases illustrating use of serology and biopsy in suspected celiac disease Case 1: 21 year-old man with mild IBS symptoms, more frequent loose stools over the past year along with some fatigue. He is not anemic and his weight is stable. His mother has celiac disease, and he wonders about the possibility. What is your next step? A referral to dietician to start gluten-free diet B check TTG IgA C check HLA-DQ2/DQ8 D referral for upper endoscopy

52 5 mini-cases illustrating use of serology and biopsy in suspected celiac disease Case 2: 48 year-old woman recently found to have significant osteoporosis on DXA scan. TTG IgA was checked and found to be 31.2 U/ml (normal is 0-15). What is your next step? A referral to dietician to start gluten-free diet B check celiac genetic tests (HLA-DQ2, DQ8) C referral for EGD with biopsies to confirm the diagnosis

53 5 mini-cases illustrating use of serology and biopsy in suspected celiac disease Case 3: 48 year-old woman recently found to have significant osteoporosis on DXA scan. TTG IgA was checked and found to be >300 U/ml (normal is 0-15). What is your next step? A referral to dietician to start gluten-free diet B check celiac genetic tests (HLA-DQ2, DQ8) C referral for EGD with biopsies to confirm the diagnosis

54 5 mini-cases illustrating use of serology and biopsy in suspected celiac disease Case 4: 21 year-old woman with longstanding bloating and constipation; found to have modestly elevated TTG IgA (54.5 IU/ml). She was told she has celiac disease and she started a gluten-free diet 3 months ago. What is your next step? A repeat TTG IgA to see if titers have decreased B referral for endoscopy to confirm the diagnosis of celiac disease C recommend resuming full-gluten diet for at least 2 weeks before EGD with biopsies

55 5 mini-cases illustrating use of serology and biopsy in suspected celiac disease Case 5: 21 year-old man with 1 year of intermittent diarrhea, bloating and upper abdominal pain. An EGD was done, and duodenal biopsies revealed mild villus blunting and increased intraepithelial lymphocytes (IELs). TTG IgA was subsequently checked and was negative at 1.5 U/ml (normal is 0-15). What is your next step? A referral to dietician to start gluten-free diet B look for other causes of villus blunting (e.g., Giardia) C start IBS treatments (probiotics, fiber, TCA)

56 Villous Atrophy with Negative Celiac Serologies? Histological mimics of CD include: -Giardia -CVID -Peptic injury -Autoimmune enteritis -Radiation -Whipple s disease -Collagenous and tropical sprue -Eosinophilic enteritis -HIV enteropathy -Lymphoma -Crohn s -Other food allergies

57 Treatment Only accepted treatment is strict, lifelong adherence to a gluten-free diet (wheat, rye, barley and initially oats) Treatment of nutritional deficiency states (iron, folate, vitamin B12, zinc, copper) Determination of bone mineral density to assess for osteoporosis Presutti et al AFP 2007

58 A gluten-free diet is one of the most difficult treatments we recommend to our patients GFD can cost as much as 3x vs. regular diet Limitations in access to GF foods Impacts social and professional life Gluten-free foods usually not fortified (thiamine, folate, iron, B2, niacin) Relatively higher fat, sugar, protein content can lead to excessive weight gain Lower fiber constipation in patients with large IBS overlap

59 New approaches to the treatment of celiac disease Approach Example Class Status Topical steroid Budesonide Small molecule Available Immune modulation Intestinal barrier enhancement anti-ccr9 blockade; humanized IL-15 specific antibody Zonulin antagonist (Larazotide) Monoclonal antibody; parasite Peptide Phase 1-2 Phase 2b Glutenase ALV003 Peptide Phase 2 Immunotherapy Nexvax2; COUR-NP-GLI Peptide; nanoparticle Discovery- Phase 1b Gluten sequestration BL-7010 Non-absorbable polymer with high affinity for gliadins Transglutaminase inhibition HLA-DQ2 blockade Gluten tolerization Dihydroisoxazoles, ZED- 101 Dimeric/cyclic gluten peptide analogues Genetically modified Lactococcus lactis Phase 1/2 Small molecule Phase 1 Peptide Bacteria discovery discovery

60 Takeaway points in celiac disease Atypical or non-classical presentation is now the most common presentation Consider the diagnosis in the setting of typical GI symptoms and family history, as well as osteoporosis, arthritis, infertility, fatigue, constipation, thyroid, skin and neurologic disease TTG IgA is the best initial test if celiac is suspected negative predictive value is 99%; positive predictive value ~75% To make the diagnosis, one must have a positive serology (TTG or EMA) and positive biopsy consuming a full-gluten diet will increase the chances of detection